Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Non-Current Deffered Revenue (2016 - 2025)

Apyx Medical's Non-Current Deffered Revenue history spans 11 years, with the latest figure at $1.0 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 6.08% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $1.0 million, down 6.08%, while the annual FY2025 figure was $1.0 million, 6.08% down from the prior year.
  • Non-Current Deffered Revenue reached $1.0 million in Q4 2025 per APYX's latest filing, down from $1.2 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $1.4 million in Q4 2022 to a low of $855000.0 in Q1 2021.
  • Average Non-Current Deffered Revenue over 5 years is $1.2 million, with a median of $1.2 million recorded in 2023.
  • Peak YoY movement for Non-Current Deffered Revenue: skyrocketed 113.04% in 2021, then dropped 11.51% in 2023.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $1.3 million in 2021, then increased by 6.42% to $1.4 million in 2022, then dropped by 11.51% to $1.2 million in 2023, then decreased by 10.27% to $1.1 million in 2024, then dropped by 6.08% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for APYX's Non-Current Deffered Revenue are $1.0 million (Q4 2025), $1.2 million (Q3 2025), and $1.2 million (Q2 2025).